Navigation Links
IMPAKT -- Translational research breast cancer conference
Date:4/11/2013

n as possible:
  • Biomarker data including
    • Predicting risk for late metastasis: the PMA50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: a study on 1,478 patients from the ABCSG-8 trial (53 O)
    • Prognostic and predictive value of IHC4 and ERB1 in the integroup exemestane study (IES) on behalf of the pathies investigators (55 O)
    • Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer (54 O)
    • Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to pre-operative trastuzumab vs. trastuzumab + everolimus in patients with early breast cancer: UNICANCER RADHER trial results (56 O)
  • Heterogeneity of breast cancer including
    • Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers (40 O)
    • Heterogeneity of genomic signatures in breast cancer core biopsy (41 O)
    • Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing (42 O)

Press conference

Thursday, 2 May 2013, 10:45-11:45 (CEST)

Hosts: Martine Piccart, Jules Bordet Institute, Head of Chemotherapy Unit, Brussels, Belgium, IMPAKT Co-Founder Peter Dubsky, Vienna General Hospital (AKH) - Medizinische Universitt Wien, Vienna, Austria, IMPAKT2013 Scientific Chair Andrew Tutt, King's College London Guy's Hospital, London, United Kingdom, IMPAKT2013 Executive Chair

BIG and ESMO welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy < '/>"/>

Contact: ESMO PRess Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fourth IMPAKT Breast Cancer Conference
2. Hot topics in translational bone research at IOF-ESCEO 3rd Pre-Clinical Symposium
3. Autism Speaks and SAGE® Labs develop rat models for translational autism research
4. Elsevier launches new open access journal: Applied and Translational Genomics
5. BUSM researchers identify novel approach to study COPD and treatment efficacy
6. LSUHSC research discovers new drug target for metastatic breast cancer
7. Researchers call for marine observation network
8. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
9. Feinstein Institute collaborates with GSK, UPenn, MIT to research bodys electrical impulses
10. U-M researchers find new way to clear cholesterol from the blood
11. New cutting-edge cell research will lead to safer medical experiments on humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... (March 18, 2009) As any parent knows, children ... University of Washington and the Monell Center indicates that ... and is related to children,s high growth rate. ... sense because when growth is rapid, caloric demands increase. ...
... Mrs. Bruce Reid recorded seeing both a male and ... 1938, Oscar McKinley Bryans observed a ruby-throated hummingbird in ... apple trees were blooming. These are just two of ... on notecards in government files. The cards record more ...
... 2009 Dr. Daniel Von Hoff, Physician-In-Chief of the ... recognizing his achievements in cancer research. Dr. Von ... Clinical Research Services at Scottsdale Healthcare, will be recognized ... special report this month in Arizona Business Magazine. ...
Cached Biology News:Liking sweets makes sense for kids 2It's for the birds 2It's for the birds 3TGen's Dr. Von Hoff wins award for cancer research 2
(Date:11/28/2014)... 28, 2014 The American Association ... University’s School of Nursing with a very prestigious ... program. The 2014 Innovations in Professional Nursing Education ... schools and supports them as they re-envision traditional ... at AACN’s annual meeting in Washington, D.C. to ...
(Date:11/27/2014)... Research and Markets  has announced the ... 2014" report to their offering. ... Acid Industry Report 2014 is a professional and in-depth ... acid industry. The report provides a basic ... industry chain structure. The palmitic acid market analysis is ...
(Date:11/27/2014)... -- Calcivis, a medical devices company ... today announces that it has completed a first ... System. The Calcivis Caries Activity Imaging ... combination designed to transform the assessment and management ... unique, proprietary bioluminescence approach combined with a specialised ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
Breaking Biology Technology:American Association of Colleges of Nursing honors Fairfield University’s School of Nursing for Re-envisioning Nursing Education 2Global Palmitic Acid Industry Report 2014 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
Human PDGF R beta MAb (Clone # PR7212)...
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: